ODYSSEY LONG TERM Trial design: Participants with heterozygous familial hypercholesterolemia or high CV risk on statin therapy were randomized to alirocumab 150 mg SQ injection every 2 weeks (n = 1,553) vs. placebo SQ injection every 2 weeks (n = 788). (p < 0.0001) Results From baseline to 24 weeks, the change in LDL-C: -61% for alirocumab compared with 0.8% for placebo (p < 0.0001) This reduction was maintained to 52 weeks; LDL-C: 53 mg/dl with alirocumab vs. 123 mg/dl with placebo Percent change in LDL-C from baseline to 24 weeks 0.8 % Conclusions Among participants with heterozygous familial hypercholesterolemia or high CV risk, alirocumab resulted in a large reduction in LDL-C compared with placebo, which was maintained to 52 weeks -61 Alirocumab Placebo Presented by Dr. Jennifer Robinson at ESC 2014